Peter Honig

Part of AstraZeneca PLC, AstraZeneca LP is a pharmaceutical company that focuses on developing and commercializing prescription drugs for various therapeutic areas. The private company is based in Wilmington, DE.

Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

Alopexx Enterprises LLC engages in investing and managing health care companies. It develops medical therapies and devices for infectious diseases, oncology, central nervous system, and orphan diseases. The firm commercializes an alternative for the treatment and prevention of staphylococcal and other bacterial infections and animal vaccines. The company was founded by Daniel R. Vlock, Deborah Ramsdell and Christine de los Reyes in 2011 and is headquartered in Concord, MA.

Accelerating Therapeutics for Opportunities in Medicine (ATOM) is an American company that focuses on molecular design and modeling programs. The private company works with open-source software and AMPL packages to build models and analyze data. The company collaborates with Lawrence Livermore National Laboratory scientists to fight against COVID-19 by combining artificial intelligence/machine learning, bioinformatics, and supercomputing to help discover drugs. ATOM shares updates about their new partners, technical team members, and presentations on their website.

Alopexx, Inc. develops novel, broad-spectrum immune medicated therapeutics for the prevention and treatment of bacterial, fungal and parasitic microbial infections. The company was founded by Daniel R. Vlock and Gerald B. Pier and is headquartered in Cambridge, MA.

Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya.